Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies. - Wikidata - wikimedia - TriplyDB

Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.

Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.

http://www.wikidata.org/entity/Q44533720

about

The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection Recent advances in renal transplantation: antibody-mediated rejection takes center stage The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation.Rituximab in the treatment of refractory late acute antibody-mediated rejection: Our initial experience.Many de novo donor-specific antibodies recognize β2 -microglobulin-free, but not intact HLA heterodimers.Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection.Antibody-mediated rejection in pediatric kidney transplantation: pathophysiology, diagnosis, and management.Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant.mTOR inhibitors and risk of chronic antibody-mediated rejection after kidney transplantation: where are we now?Bortezomib in the treatment of antibody-mediated rejection in pediatric kidney transplant recipients: A multicenter Midwest Pediatric Nephrology Consortium study.Belatacept As an Alternative to Calcineurin Inhibitors in Patients with Solid Organ Transplants.Early subclinical inflammation correlates with outcomes in positive crossmatch kidney allografts.Therapy Modalities for Antibody Mediated Rejection in Renal Transplant Patients.Successful treatment of severe acute antibody-mediated rejection of renal allografts with bortezomib--a report of two pediatric cases.Rituximab use in late antibody-mediated rejection Acute Rejection in Renal Transplant Patients of a Hospital in Bogota, Colombia Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection.Complement C5 Inhibition Reduces T Cell-Mediated Allograft Vasculopathy Caused by Both Alloantibody and Ischemia Reperfusion Injury in Humanized Mice.Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation.A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.Triptolide inhibits donor-specific antibody production and attenuates mixed antibody-mediated renal allograft injury.The lack of Lazarus effect with proteasome inhibition.Acute rejection.Graft outcomes following diagnosis of post-transplant lymphoproliferative disease in pediatric kidney recipients: a retrospective study.Molecular Assessment of Microcirculation Injury in Formalin-Fixed Human Cardiac Allograft Biopsies With Antibody-Mediated Rejection.Antibody-mediated rejection: New approaches in prevention and management.[Rehabilitation after kidney transplantation: Old problems and new structures].

P2860

Q26774993-DA384FE5-62AB-44B3-8440-AE96C6C0D280 Q26862195-8CCF484F-43B7-4A14-A4BF-2DAE71CC0EDB Q35659332-4F9439AB-FEB7-43D0-85D4-AFB3452025D4 Q36240178-4B3510D6-CF6E-42E3-A58E-0231FDAA9596 Q37241071-C153D4EA-4C14-4E89-AFED-4526F77A3AD2 Q37352506-E70C4B4A-6EEE-40C4-A774-D2F55C4FC996 Q38282840-E464797A-FF94-4AAD-974F-C20752AF2F40 Q38392458-50AAFE1A-C462-4950-B116-DC39C225FE7A Q38731333-400FF767-11F4-462C-A3D5-E4402F5B03A2 Q38818479-E4FFAE0D-6E84-48C5-A852-29AFA4C76FFE Q39018530-6B16FA29-3C35-4BF2-A75B-31610B014246 Q39350215-15C80AAC-58CE-4699-B675-C1E4E68A2B6C Q39736122-829AADB7-2FD6-4B94-AB38-814ACC6DBD2C Q40745610-8BF7B810-5B18-4B35-A5E0-28ABA287E54A Q40958100-F72F63E8-65AB-40B1-AE30-8FCE80EFE55A Q41041729-F04B3266-BD63-4F70-B85B-240968E456A7 Q41358191-3CCDF43E-87A4-4226-B119-EB0F078CDCC3 Q41495990-7A975FC8-AF03-4BD8-B4EE-98C795A304EE Q41631576-FA2F48AD-F28B-49C7-8E61-E59587F34D70 Q42372206-918D2F0C-A583-49D2-AEAD-336B1B2AA01A Q47292306-ED7BE979-8FB9-40EC-BAFF-32835AF2B30C Q47311433-A81F8882-5216-47EA-A21A-433E327FAE59 Q47443910-40F0B24C-3180-460E-BA0C-781D2AFE0FFD Q47744928-EDE032CC-9A54-44FF-B0CF-73662C78E1B0 Q47987136-74A239B7-6D69-4E29-8F71-8F110B79B2F5 Q48165787-6668EE98-8DBA-47EF-8F21-47CC56AF4CE3 Q52401610-6A646396-B33A-4477-A8C3-7E1A15BF1A68 Q52859573-B21B34FD-58FC-4279-94C1-990ECD3E78A9

P2860

Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.

http://www.wikidata.org/entity/Q44533720

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Late antibody-mediated rejecti ...... ventional and novel therapies.

@en

Late antibody-mediated rejecti ...... ventional and novel therapies.

@nl

type

label

Late antibody-mediated rejecti ...... ventional and novel therapies.

@en

Late antibody-mediated rejecti ...... ventional and novel therapies.

@nl

prefLabel

Late antibody-mediated rejecti ...... ventional and novel therapies.

@en

Late antibody-mediated rejecti ...... ventional and novel therapies.

@nl

P1433

Q44533720-3AD4D178-3FD4-46C7-97FE-A4F3C9D082E7

P1476

Q44533720-0CA0A9A8-4309-435A-9660-874BF4C5BF0E

P2093

Q44533720-047132ED-325B-4183-BA5B-8344023AC295

Q44533720-10A4FF30-2ABA-4EF9-BEFC-F4E769EB8B7E

Q44533720-1C760C90-BF51-4B60-A7AF-AB7A1BC8BA5F

Q44533720-59DC5665-313E-48F3-B152-3C2DD4548B90

Q44533720-6281D2CF-D7C1-47F4-9BFC-B2069E016B05

Q44533720-74378869-86D8-4190-9D1F-CF5986F05DE1

Q44533720-96920994-4616-476D-BF50-A4B3EB0E8A35

Q44533720-D67D54D2-1AE6-4EBE-A5B6-EE8745A26FA3

Q44533720-FD18B185-6E42-46D4-B7C4-0B3238D4AEEE

P304

Q44533720-3404FE46-7A4F-444A-AA89-70D54EE2FBA7

P31

Q44533720-1E402E8B-E2D8-438F-BF51-F7330488BBE5

P356

Q44533720-0DFD6F21-89E1-4FE6-9BF6-44D2D7177113

P433

Q44533720-3C905D3C-74A0-49CF-ADB8-7BE711C12F8B

P478

Q44533720-04BB7D46-7BCE-44AF-AFF2-89089995ABA1

P50

Q44533720-13B3650A-A261-4EF2-8EE3-0EB78EE66D2C

Q44533720-59A7E649-3B9E-4D06-A902-49ABA00B3197

P577

Q44533720-D012A706-01F5-4AB6-8372-9EFD73572074

P698

Q44533720-90944260-92E5-42E0-BDD7-38AC6D0B2325

P921

Q44533720-E797B9DF-BE26-4592-8B96-99BA5AD9E92E

P356

01.TP.0000442503.85766.91

P1433

Transplantation

P1476

Late antibody-mediated rejecti ...... nventional and novel therapies

@en

P2093

Andrea A Zachary

http://www.w3.org/2001/XMLSchema#string

Bassam G Abu Jawdeh

http://www.w3.org/2001/XMLSchema#string

Bhavna Bhasin

http://www.w3.org/2001/XMLSchema#string

Brandon Trollinger

http://www.w3.org/2001/XMLSchema#string

Edward Kraus

http://www.w3.org/2001/XMLSchema#string

Hamid Rabb

http://www.w3.org/2001/XMLSchema#string

Lois J Arend

http://www.w3.org/2001/XMLSchema#string

Lorraine C Racusen

http://www.w3.org/2001/XMLSchema#string

Robert A Montgomery

http://www.w3.org/2001/XMLSchema#string

P304

1240-1246

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/01.TP.0000442503.85766.91

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24937198

http://www.w3.org/2001/XMLSchema#string

P921